The patients, a 71-year-old male and a 62 year-old-male, both on long-term warfarin therapy, presented to the emergency department with symptoms of COVID-19.
Your search for Warfarin returned 16 results
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
The patient developed a generalized maculopapular rash approximately 3 hours after receiving warfarin.
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Quality improvement effort tied to decrease in major bleeding without increase in thrombotic events
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.